Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

Aristada (aripiprazole lauroxil) extended release injection approved to treat adults with schizophrenia

On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is administered by a health care professional every four to six weeks using an injection in the arm or buttocks.

9 Oct 2015

Study shows antipsychotic medication increases death risk in patients with Parkinson's disease psychosis

Antipsychotic drugs may increase the risk of death in people with Parkinson's disease psychosis (PDP), according to a new study led by researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London.

1 Oct 2015

Mylan releases generic version of Invega in the U.S.

Mylan N.V. today announced the U.S. launch of Paliperidone Extended-Release Tablets 1.5 mg, 3 mg, 6 mg and 9 mg, the generic version of Janssen's Invega.

28 Sep 2015

Two-drug combination relieves depression in older adults

More than half of older adults with clinical depression don't get better when treated with an antidepressant. But results from a multicenter clinical trial that included Washington University School of Medicine in St. Louis indicates that adding a second drug — an antipsychotic medication — to the treatment regimen helps many of those patients.

28 Sep 2015

ProPhase partners with Multi Health Systems to standardize electronic adaptations of PANSS

ProPhase LLC, a global provider of applied measurement expertise, is announcing its partnership with Multi Health Systems, a Canadian publisher of psychological assessments and healthcare outcomes, to optimize and standardize electronic adaptations of the Positive and Negative Syndrome Scale (PANSS).

14 Sep 2015

Researchers examine neuroanatomical signature of schizophrenia in different ethnic groups

While it is known that the incidence and outward symptoms of schizophrenia are strongly influenced by ethnic factors--for instance, patients from Asian ethnicities are more likely to experience visual hallucinations, whereas patients from western cultures and Caucasian ethnicities are more likely to suffer from auditory hallucinations--it was unclear if brain deficits would differ amongst suffers from various ethnic backgrounds.

14 Sep 2015

Special issue provides update on mental health diagnosis and treatment of older adults

The aging of the population, shifting diagnostic criteria, and new health care policy initiatives are some of the factors driving changes in mental health treatment for older Americans, according to the September special issue of the Harvard Review of Psychiatry. The journal is published by Wolters Kluwer.

10 Sep 2015

Phase III trial results show cariprazine effective in treating negative symptoms associated with schizophrenia

Results of a clinical trial seem to show the first effective treatment for the negative symptoms - withdrawal, lack of emotion, and apathy - associated with schizophrenia.

31 Aug 2015

Brain scans may help predict patients' response to antipsychotic drug treatment

Investigators at The Feinstein Institute for Medical Research have discovered that brain scans can be used to predict patients' response to antipsychotic drug treatment. The findings are published online in the latest issue of The American Journal of Psychiatry.

28 Aug 2015

Medicaid could save billions as patents for several blockbuster antipsychotic medications expire

Medicaid is expected to save billions of dollars a year as patents for several blockbuster antipsychotic medications expire and use of generic versions of these drugs increases, according to a new study by researchers at the University of Maryland School of Medicine. These savings may provide relief from the high costs of these medications and allow policymakers to lift restrictions on patients' access, the researchers argue.

21 Aug 2015

15th Annual Geriatric Health Care Symposium now open for registration

Registration is now open for the 15th Annual Geriatric Health Care Symposium, "Maximizing Independence for Optimal Aging," presented by the University of Louisville Institute for Sustainable Health & Optimal Aging.

3 Aug 2015

Diagnosing psychiatric disorder may not be as important as prescribing effective treatment

Nailing the diagnosis of a psychiatric disorder may not be important in prescribing effective treatment, according to Mark Zimmerman, M.D., a clinical researcher at Rhode Island Hospital. His opinion editorial was published online today in the Journal of Clinical Psychiatry.

24 Jul 2015

Allergan announces U.S. availability of SAPHRIS 2.5 mg tablets for children with bipolar I disorder

Allergan plc today announced that SAPHRIS (asenapine) 2.5 mg sublingual (placed under the tongue) black-cherry flavored tablets are available in pharmacies throughout the U.S. In March 2015, the U.S. Food and Drug Administration approved SAPHRIS for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (ages 10 – 17).

17 Jul 2015

Study identifies trends in use of antipsychotic medications in young people in the U.S.

Despite concerns that use of antipsychotic medications in treating young people has increased, use actually declined between 2006 and 2010 for children ages 12 and under, and increased for adolescents and young adults.

2 Jul 2015

Use of antipsychotic drugs more common in boys than girls, research shows

Boys are more likely than girls to receive a prescription for antipsychotic medication regardless of age, researchers have found.

2 Jul 2015

FAU awarded $2.1 million to examine effectiveness of antipsychotic medication for schizophrenia

Florida Atlantic University's Charles E. Schmidt College of Medicine was recently awarded a $2.1 million, two-year contract by Otsuka America Pharmaceutical Inc. to conduct a study to examine the effectiveness of an injectable long-acting antipsychotic medication for schizophrenia and its impact on 30-day hospital readmission rates.

1 Jul 2015

Long-acting injectable antipsychotic medication benefits people with schizophrenia

Schizophrenia, which affects 2 million to 3 million people in the U.S., causes hallucinations, delusions and disorganization. Left untreated, the disease can cause a significant loss in quality of life, including unemployment and estrangement from loved ones. But many people with schizophrenia can control the disorder and live without symptoms for several years if they consistently take prescribed antipsychotic medication, typically a daily pill.

25 Jun 2015

Alexza updates, amends ADASUVE (Staccato loxapine) commercial partnerships with Ferrer and Teva

Alexza Pharmaceuticals, Inc. today announced that it has updated and amended its ADASUVE (Staccato loxapine) commercial partnerships with Grupo Ferrer Internacional, S.A. and Teva Pharmaceutical Industries Ltd. Ferrer is Alexza's commercial partner for ADASUVE in the European Union, Latin America, the Commonwealth of Independent States and other countries in Europe.

19 Jun 2015

New data shows psychotropic medication use among Medicaid-enrolled foster children in Pennsylvania

Today, the Department of Human Services, in partnership with PolicyLab at The Children's Hospital of Philadelphia, released new data on psychotropic medication use among Medicaid-enrolled Pennsylvania children in foster care, as well as the state's action plan to address the findings.

16 Jun 2015

HQO report shows variations across Ontario's long-term care homes regarding antipsychotic drug use

There are major differences across Ontario's long-term care homes in the percentage of residents who are being prescribed antipsychotic medications, according to Looking for Balance, a report from Health Quality Ontario, the provincial advisor on health care quality.

20 May 2015